-+ 0.00%
-+ 0.00%
-+ 0.00%

Skye Bioscience' Interim 52-week Data From the Combination Therapy Arms In Extension Phase of Phase 2a CBeyond Proof-of-concept Study of Nimacimab Shows 22.3% Total Weight Loss

Benzinga·02/02/2026 12:10:01
Listen to the news
  • 22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses
  • Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantage
  • Strong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period